Table 4.
Peri-procedural drug therapy
| Drug type | Drug | All | De novo | BMS-ISR | DES-ISR | p value | |
|---|---|---|---|---|---|---|---|
| Patients | 481 | 377 | 19 | 85 | – | ||
| Pre PCI | APT | 600 mg clopidogrel | 195 (40.5%) | 158 (41.9%) | 6 (31.6%) | 31 (36.5%) | < 0.001 |
| 300 mg clopidogrel | 46 (9.6%) | 36 (9.5%) | 2 (10.5%) | 8 (9.4%) | |||
| 75 mg clopidgrel | 36 (7.5%) | 30 (8.0%) | 2 (10.5%) | 4 (4.7%) | |||
| ASA only | 60 (12.5%) | 34 (9.0%) | 7 (36.8%) | 19 (22.4%) | |||
| 180 mg ticagrelor | 61 (12.7%) | 50 (13.3%) | 0 (0.0%) | 11 (12.9%) | |||
| 90 mg ticagrelor | 1 (0.2%) | 0 (0.0%) | 1 (5.3%) | 0 (0.0%) | |||
| 60 mg prasugrel | 45 (9.4%) | 41 (10.9%) | 1 (5.3%) | 3 (3.5%) | |||
| 10 mg prasugrel | 5 (1.0%) | 5 (1.3%) | 0 (0.0%) | 0 (0.0%) | |||
| no preloading | 32 (6.7%) | 23 (6.1%) | 0 (0.0%) | 9 (10.6%) | |||
| Post PCI | APT | Clopidogrel | 341 (70.9%) | 268 (71.1%) | 16 (84.2%) | 57 (67.1%) | 0.087 |
| Ticagrelor | 82 (17.0%) | 58 (15.4%) | 2 (10.5%) | 22 (25.9%) | |||
| Prasugrel | 56 (11.6%) | 50 (13.3%) | 1 (5.3%) | 5 (5.9%) | |||
| Other | 2 (0.4%) | 1 (0.3%) | 0 (0.0%) | 1 (1.1%) | |||
| Triple therapy | DAPT + vitamin K antagonist or NOAC | 7 (1.5%) | 6 (1.6%) | 0 (0.0%) | 1 (1.2%) | 0.829 | |
APT antiplatelet therapy, ASA acetylsalicylic acid, BMS bare metal stent, DAPT dual antiplatelet therapy, DES drug-eluting stent, ISR in-stent restenosis, NOAC non-vitamin K oral anticoagulant, PCI percutaneous coronary intervention